AIRLINK 190.16 Increased By ▲ 1.41 (0.75%)
BOP 12.83 Decreased By ▼ -0.11 (-0.85%)
CNERGY 7.21 Decreased By ▼ -0.01 (-0.14%)
FCCL 43.41 Increased By ▲ 2.86 (7.05%)
FFL 15.39 Increased By ▲ 0.29 (1.92%)
FLYNG 26.37 Increased By ▲ 0.93 (3.66%)
HUBC 130.61 Decreased By ▼ -1.89 (-1.43%)
HUMNL 13.84 Increased By ▲ 0.39 (2.9%)
KEL 4.71 Decreased By ▼ -0.17 (-3.48%)
KOSM 6.70 Increased By ▲ 0.22 (3.4%)
MLCF 49.51 Increased By ▲ 2.37 (5.03%)
OGDC 204.81 Increased By ▲ 0.01 (0%)
PACE 6.41 Increased By ▲ 0.14 (2.23%)
PAEL 40.81 Increased By ▲ 1.82 (4.67%)
PIAHCLA 16.85 Increased By ▲ 0.02 (0.12%)
PIBTL 8.69 Increased By ▲ 0.58 (7.15%)
POWER 11.02 Increased By ▲ 0.33 (3.09%)
PPL 174.44 Increased By ▲ 0.79 (0.45%)
PRL 34.71 Increased By ▲ 0.61 (1.79%)
PTC 24.99 Increased By ▲ 1.50 (6.39%)
SEARL 97.99 Decreased By ▼ -1.01 (-1.02%)
SILK 1.09 Decreased By ▼ -0.01 (-0.91%)
SSGC 31.10 Increased By ▲ 0.48 (1.57%)
SYM 17.81 Decreased By ▼ -0.02 (-0.11%)
TELE 8.30 Increased By ▲ 0.11 (1.34%)
TPLP 12.18 Increased By ▲ 0.06 (0.5%)
TRG 61.66 Increased By ▲ 0.55 (0.9%)
WAVESAPP 11.67 Decreased By ▼ -0.05 (-0.43%)
WTL 1.48 No Change ▼ 0.00 (0%)
YOUW 4.18 Decreased By ▼ -0.03 (-0.71%)
AIRLINK 190.16 Increased By ▲ 1.41 (0.75%)
BOP 12.83 Decreased By ▼ -0.11 (-0.85%)
CNERGY 7.21 Decreased By ▼ -0.01 (-0.14%)
FCCL 43.41 Increased By ▲ 2.86 (7.05%)
FFL 15.39 Increased By ▲ 0.29 (1.92%)
FLYNG 26.37 Increased By ▲ 0.93 (3.66%)
HUBC 130.61 Decreased By ▼ -1.89 (-1.43%)
HUMNL 13.84 Increased By ▲ 0.39 (2.9%)
KEL 4.71 Decreased By ▼ -0.17 (-3.48%)
KOSM 6.70 Increased By ▲ 0.22 (3.4%)
MLCF 49.51 Increased By ▲ 2.37 (5.03%)
OGDC 204.81 Increased By ▲ 0.01 (0%)
PACE 6.41 Increased By ▲ 0.14 (2.23%)
PAEL 40.81 Increased By ▲ 1.82 (4.67%)
PIAHCLA 16.85 Increased By ▲ 0.02 (0.12%)
PIBTL 8.69 Increased By ▲ 0.58 (7.15%)
POWER 11.02 Increased By ▲ 0.33 (3.09%)
PPL 174.44 Increased By ▲ 0.79 (0.45%)
PRL 34.71 Increased By ▲ 0.61 (1.79%)
PTC 24.99 Increased By ▲ 1.50 (6.39%)
SEARL 97.99 Decreased By ▼ -1.01 (-1.02%)
SILK 1.09 Decreased By ▼ -0.01 (-0.91%)
SSGC 31.10 Increased By ▲ 0.48 (1.57%)
SYM 17.81 Decreased By ▼ -0.02 (-0.11%)
TELE 8.30 Increased By ▲ 0.11 (1.34%)
TPLP 12.18 Increased By ▲ 0.06 (0.5%)
TRG 61.66 Increased By ▲ 0.55 (0.9%)
WAVESAPP 11.67 Decreased By ▼ -0.05 (-0.43%)
WTL 1.48 No Change ▼ 0.00 (0%)
YOUW 4.18 Decreased By ▼ -0.03 (-0.71%)
BR100 11,961 Increased By 56.1 (0.47%)
BR30 35,673 Increased By 313.4 (0.89%)
KSE100 113,739 Increased By 396.7 (0.35%)
KSE30 35,328 Increased By 35.3 (0.1%)

LONDON: British drugmaker GlaxoSmithKline on Tuesday snapped up US biopharmaceutical firm Affinivax for up to $3.3 billion, expanding further into vaccines before the demerger of its consumer health care arm.

The London-listed company has agreed to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones for Affinivax.

“GSK plc today announced that it has entered into a definitive agreement to acquire Affinivax, Inc,” it said in a statement.

“Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines,” it added.

The Cambridge, Massachusetts-based firm specialises in vaccines for diseases including meningitis, pneumonia and bloodstream infections.

“The proposed acquisition further strengthens our vaccines research and development (R&D) pipeline, provides access to a new, potentially disruptive technology, and broadens GSK’s existing scientific footprint in the Boston area,” said GSK’s chief scientific officer Hal Barron.

“We look forward to working with the many talented people at Affinivax to combine our industry-leading development, manufacturing, and commercialisation capabilities to make this exciting new technology available to those in need,” added Barron, who is also the group’s president of R&D.

The acquisitions come as chief executive Emma Walmsley seeks to reshape GSK after she faced fierce investor criticism over the company’s delay in producing Covid jabs and treatments.

Comments

Comments are closed.